BioCentury
ARTICLE | Finance

Sigilon nears first clinical test of cell shielding tech with $80M series B

March 17, 2020 11:04 AM UTC
Updated on Mar 18, 2020 at 2:47 PM UTC

With its $80.3 million series B round, Sigilon is planning to bring the first of its shielded cell therapies into the clinic, while also advancing toward INDs on four other programs.

Canada Pension Plan Investment Board, Longevity Vision Fund and funds managed by BlackRock participated in Sigilon Therapeutics Inc.’s untranched round, as did existing investors Flagship Pioneering and Eli Lilly and Co. (NYSE:LLY)...

BCIQ Company Profiles

Sigilon Therapeutics Inc.